We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




New Procedure Found Safe and Effective for Patients Undergoing Transcatheter Mitral Valve Replacement

By HospiMedica International staff writers
Posted on 05 May 2025

In the United States, approximately four million people suffer from mitral valve regurgitation, the most common type of heart valve disease. More...

As an alternative to open-heart surgery, transcatheter mitral valve replacement (TMVR) provides a minimally invasive option to replace a malfunctioning mitral valve. However, a significant complication of TMVR is left ventricular outflow tract (LVOT) obstruction, which restricts blood flow from the left ventricle and can lead to heart failure. This condition is associated with a high mortality rate. Balloon-assisted anterior mitral leaflet modification (BATMAN) is a new technique designed to prevent LVOT obstruction during TMVR, but its safety and effectiveness have not been fully established. Now, new findings from a large, international registry, presented as late-breaking clinical research at the SCAI 2025 Scientific Sessions, demonstrated that BATMAN is a safe and effective method that reduces procedure times for patients undergoing TMVR.

The study, led by Atlantic Health System (Morristown, NJ, USA), involved 41 high-risk patients undergoing transseptal TMVR with balloon-assisted anterior mitral leaflet (AML) modification across 12 structural heart centers in the United States, Canada, and Europe. The primary efficacy endpoint was defined as the successful completion of TMVR with no LVOT obstruction (mean gradient >50 mmHg) and no procedural deaths. The primary safety endpoint was the in-hospital composite of death, stroke, or major cardiac structural complications, as assessed by the mitral valvular academic consortium (MVARC) criteria. The primary efficacy endpoint was achieved in 92.7% of the patients. Leaflet traversal and balloon laceration were successful in all cases, with no instances of residual LVOT obstruction.

The median time between leaflet traversal and valve implantation was just 28 minutes. The primary safety endpoint occurred in 9.8% of patients, which was attributed to two deaths in the Valve in Mitral annular calcification (ViM) group and one death in the Valve in Valve (ViV) group. The Valve in Ring (ViR) group experienced no primary safety events. Additionally, there were no cardiac structural complications related to the BATMAN technique, and no cases of stroke were reported. Further studies are necessary to refine the BATMAN technique and compare its effectiveness to the LAMPOON method in patients undergoing TMVR with AML modification to prevent LVOT obstruction.

“Traditionally, the LAMPOON technique and its various iterations has been used to enable TMVR in patients at high risk of LVOT obstruction; however, this technique has a steep learning curve and is technically more challenging and time-consuming,” said Gennaro Giustino, MD, Structural Interventional Cardiologist at Morristown Medical Center, Atlantic Health System and lead author of the study. "The findings from this study highlight that BATMAN may be considered as an alternative to LAMPOON associated with excellent efficacy and safety, particularly for ViR and ViV procedures, providing another option for physicians."

Related Links:
Atlantic Health System


Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Half Apron
Demi
ow Frequency Pulse Massager
ET10 L
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.